Manulife (Manufacturers Life Insurance)
KROS icon

Manulife (Manufacturers Life Insurance)’s Keros Therapeutics KROS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,494
Closed -$182K – 2908
2025
Q3 		$182K Sell
11,494
-957
-8% -$14.1K ﹤0.01% 2615
2025
Q2 		$166K Buy
12,451
+988
+9% +$13.3K ﹤0.01% 2628
2025
Q1 		$117K Sell
11,463
-28,893
-72% -$335K ﹤0.01% 2661
2024
Q4 		$639K Buy
40,356
+23,550
+140% +$1.22M ﹤0.01% 2115
2024
Q3 		$976K Sell
16,806
-27
-0.2% -$1.33K ﹤0.01% 1942
2024
Q2 		$769K Buy
16,833
+2,517
+18% +$135K ﹤0.01% 1995
2024
Q1 		$948K Buy
14,316
+2,875
+25% +$170K ﹤0.01% 1886
2023
Q4 		$455K Sell
11,441
-18,433
-62% -$578K ﹤0.01% 2219
2023
Q3 		$952K Buy
29,874
+2,567
+9% +$95.8K ﹤0.01% 1762
2023
Q2 		$1.1M Buy
27,307
+1,513
+6% +$66.3K ﹤0.01% 1604
2023
Q1 		$1.1M Buy
25,794
+5,690
+28% +$287K ﹤0.01% 1583
2022
Q4 		$965K Buy
20,104
+13,293
+195% +$621K ﹤0.01% 1626
2022
Q3 		$256K Buy
+6,811
New +$236K ﹤0.01% 2406
2022
Q2 		– Sell
-6,565
Closed -$357K – 3076
2022
Q1 		$357K Sell
6,565
-1,644
-20% -$84.4K ﹤0.01% 2399
2021
Q4 		$480 Sell
8,209
-299
-4% -$14.9K ﹤0.01% 2291
2021
Q3 		$337K Sell
8,508
-504
-6% -$17.9K ﹤0.01% 2577
2021
Q2 		$383K Buy
9,012
+1,433
+19% +$77.6K ﹤0.01% 2616
2021
Q1 		$466K Sell
7,579
-152
-2% -$9.63K ﹤0.01% 2324
2020
Q4 		$545K Buy
+7,731
New +$487K ﹤0.01% 2148

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s KROS Position: Q4 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 11,494 shares — an estimated $182K sold.

Manulife (Manufacturers Life Insurance) first reported a position in KROS in Q4 2020 and held it in 19 quarters. The position peaked at $1.1M in Q1 2023. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Manulife (Manufacturers Life Insurance) reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 11,494 Keros Therapeutics shares in Q4 2025, an estimated $182K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Keros Therapeutics in Q4 2020 and held it in 19 quarters.
  • Manulife (Manufacturers Life Insurance)'s Keros Therapeutics position peaked at $1.1M in Q1 2023.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2025, filed 13 Feb 2026.